NASDAQ:LKFT Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis $29.40 +0.35 (+1.20%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Lakefront Biotherapeutics American Depositary Shares Stock (NASDAQ:LKFT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LKFT alerts:Sign Up Key Stats Today's Range$28.50▼$29.4550-Day Range$26.13▼$30.7252-Week Range$25.68▼$36.24Volume226,585 shsAverage Volume344,931 shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$37.00Consensus RatingModerate Buy Company Overview Lakefront is a clinical-stage biotechnology company developing therapies in immunology and inflammation. Its clinical-stage portfolio includes lead asset gamgertamig, a BCMAxCD3 T-cell engager being developed for the treatment of autoimmune diseases. The company identifies, acquires, and advances therapeutic assets through business development and clinical development activities. Lakefront evaluates opportunities for portfolio expansion based on their scientific, clinical, and commercial potential. Lakefront focuses on developing medicines for diseases with unmet medical needs and advancing its product candidates through clinical development. Read More Lakefront Biotherapeutics American Depositary Shares Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreLKFT MarketRank™: 3.176199868505 of 5 starsLakefront Biotherapeutics American Depositary Shares scored higher than 64% of companies evaluated by MarketBeat, and ranked 367th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLakefront Biotherapeutics American Depositary Shares has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.Upside PotentialLakefront Biotherapeutics American Depositary Shares has a consensus price target of $37.00, representing about 25.9% upside from its current price of $29.40.Amount of Analyst CoverageLakefront Biotherapeutics American Depositary Shares has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lakefront Biotherapeutics American Depositary Shares' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lakefront Biotherapeutics American Depositary Shares are expected to decrease in the coming year, from ($1.27) to ($1.80) per share.Price to Book Value per Share RatioLakefront Biotherapeutics American Depositary Shares has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.19% of the float of Lakefront Biotherapeutics American Depositary Shares has been sold short.Short Interest Ratio / Days to CoverLakefront Biotherapeutics American Depositary Shares has a short interest ratio ("days to cover") of 9.48.Change versus previous monthShort interest in Lakefront Biotherapeutics American Depositary Shares has recently decreased by 2.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLakefront Biotherapeutics American Depositary Shares does not currently pay a dividend.Dividend GrowthLakefront Biotherapeutics American Depositary Shares does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.19 News SentimentLakefront Biotherapeutics American Depositary Shares has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lakefront Biotherapeutics American Depositary Shares this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Lakefront Biotherapeutics American Depositary Shares to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lakefront Biotherapeutics American Depositary Shares insiders have not sold or bought any company stock.Percentage Held by Insiders2.91% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by insiders.Percentage Held by Institutions32.46% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by institutions.Read more about Lakefront Biotherapeutics American Depositary Shares' insider trading history. Receive LKFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lakefront Biotherapeutics American Depositary Shares and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LKFT Stock News HeadlinesLakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell TherapeuticsOctober 14 at 4:01 PM | globenewswire.comAcquisition of Own SharesOctober 13 at 4:01 PM | globenewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 14 at 1:00 AM | Weiss Ratings (Ad)Acquisition of Own SharesOctober 6, 2026 | globenewswire.comLakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) vs. Arcus Biosciences (NYSE:RCUS) Head-To-Head ReviewOctober 5, 2026 | americanbankingnews.comAcquisition of Own SharesSeptember 29, 2026 | globenewswire.comLakefront Biotherapeutics Stock Rises 4% After Share Repurchase UpdateSeptember 24, 2026 | rttnews.comLakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC SaysSeptember 23, 2026 | marketscreener.comMSee More Headlines LKFT Stock Analysis - Frequently Asked Questions How have LKFT shares performed this year? Lakefront Biotherapeutics American Depositary Shares' stock was trading at $32.70 at the beginning of the year. Since then, LKFT shares have decreased by 10.1% and is now trading at $29.40. How were Lakefront Biotherapeutics American Depositary Shares' earnings last quarter? Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) released its quarterly earnings results on Monday, August, 10th. The biotechnology company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.97) by $1.00. The biotechnology company earned $15.47 million during the quarter, compared to the consensus estimate of $7.29 million. How do I buy shares of Lakefront Biotherapeutics American Depositary Shares? Shares of LKFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lakefront Biotherapeutics American Depositary Shares own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lakefront Biotherapeutics American Depositary Shares investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Pharming Group (PHGUF), argenex (ARGX), Advanced Micro Devices (AMD), Micron Technology (MU) and Tesla (TSLA). Company Calendar Last Earnings8/10/2026Today10/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LKFT's financial health is in the Red zone, according to TradeSmith. LKFT has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LKFT Previous SymbolNASDAQ:GLPG CIK1421876 Webwww.glpg.com Phone(321) 534-2900Fax321-534-2901Employees1,310Year Founded1999Price Target and Rating Average Price Target for Lakefront Biotherapeutics American Depositary Shares$37.00 High Price Target$45.00 Low Price Target$26.00 Potential Upside/Downside+25.9%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio32.84 Quick Ratio32.72 Sales & Book Value Annual Sales$1.26 billion Price / Sales1.54 Cash Flow$0.73 per share Price / Cash Flow40.01 Book Value$47.57 per share Price / Book0.62Miscellaneous Outstanding Shares65,900,000Free Float63,979,000Market Cap$1.94 billion OptionableOptionable Beta0.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LKFT) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYou’d Never Guess What Their European Chalet CostEric and Debbie, a couple in their 60s from Burbank, California, retired to a private chalet on a European cou...International Living | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakefront Biotherapeutics American Depositary Shares Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakefront Biotherapeutics American Depositary Shares With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
